Compare Nokia Corp (NOK) vs Summit Therapeutics Inc (SMMT) Price & Performance

Nokia (NOK) trades at $10.285, down 3.15% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89B with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.

The stock presents a valuation challenge with a high P/E of 75.09, though analyst consensus is bullish with a $17.50 price target. Upside potential is supported by AI infrastructure demand and strategic partnerships, but risks include competitive pressures, execution on growth initiatives, and volatile cash flows. The current price is well below the consensus target, indicating significant projected upside if growth catalysts materialize.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.